The First Experiences With Reassessments and Appraisals of Conditionally Approved Expensive and Orphan Drugs in the Netherlands (2006-2013)

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.308
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV


Related search